acceptance number

month of the study

age (mean+-SD)

online/face to face

full vaccinated / not

Christopher J Peterson, 2021

13 July 2021 to 3 August 2021

Male 36.75%, Females 62.82%

medical students

Kim Mannemar Sønderskov

10 December to 23 December 2021

Han nationality (95.0%)

females (69.0%) , males (31.0%)

6.7% not vacc., 7.6% first dose vaccinated, 81.9% full vacc,3.7% got booster

 (2.5%) participants were medical staff,

Dominican REpublic

female (n=658; 60%), 39.7% (n=435) were male, and 0.3% (n=3) preferred not to identify their gender.

Sinovac, AstraZeneca, Pfizer

81.9% (n=898) had completed their scheme with the second dose

31.5% (n=345) have obtained a bachelor’s degree level, 20.9% (n=229) doctorate, 27.5% (n=301) have a master’s level, 1.9% (n=21) has accomplished a PhD, , technicians6.7% and who have completed high-school 11.3% or elementary school 0.3%.

14.7% (n=161) are unemployed; the remaining 85.3% actively work in the public, private sector, or independently. A total of 43% (n=471) of participants are health personnel

20 October to 10 December 2021,

88.9%full vaccinated, 8.6% fin ish first dose, 2.4% not vaccinated

Non-Hispanic White 61.9%, Non-Hispanic Black 12.3%, Hispanic 17.4%, Asian 5.3%, Others 3.1%

Female 49.7% Male 47.6%

Ammar Abdulrahman Jairoun, 2022

25 August to 20 October 2021

(31.1%) aged 18–22, (38.4%) aged 23–26, (21.3%) aged 27–30, (4.9%) aged 31–36 and (4.2%) aged ≥ 37.

22.1% were Emirati, 22.1% were African, 19.7% were Western, 28% were Asian and 8% were Arabic.

69.1% female and 30.9% male

77% have received first two doses of the COVID-19 vaccine 

1 week from November 12, 2021

≤30>>>> 808 (46.87%)
31–40 >>>748 (43.39%))
41–50 >>>139 (8.06%)
,>50 >>29 (1.68)

Female (49.71%), male (50.29%)

23 September 2021 to 3 October 2021

83.4%females, 16.6% male

full vaccination (two doses of
Comirnaty or Spikevax or AstraZeneca or 1 dose of Johnson & Johnson The most common
vaccine administered to the respondents was Pfizer/BioNTech’s Comirnaty vaccine (74.1%),
while the schedule of (2.4%) respondents was mixed and used mRNA vaccine and a
vector vaccine.

(36.5%) were healthcare
workers

Primary (0.5%)
Lower secondary (0.4%)
Vocational (1%)
Secondary 309 (20.2%)
Higher (university degree) 1189 (77.8%)
education (77.8%).

between 26 and 31 october 2021

Age group, years 18–29 614 (26.4) 30–39 1064 (45.7) 40–49 514 (22.1) ≥50 137 (5.9)

Male (49.2) Female (50.8)

Three types of COVID-19 vaccines, including two inactivated vaccines (Sinopharm and Sinovac CoronaVac) and one adenovirus vector COVID-19 vaccine (CanSino: Ad5-nCoV), were available in Shenzhen during the study period. Completion of a primary vaccination series was defined
as receiving two doses of inactivated COVID-19 vaccine (Sinopharm and/or Sinovac
CoronaVac) or one dose of adenovirus vector COVID-19 vaccine (CanSino Ad5-nCoV),f

163 not fully vaccinated,

Junior high or below 580 (24.9) Senior high or equivalent 678 (29.1) College/university or above 1071 (46.0)

factory in shenzehn employee

united kingdom

february to march 2021

M = 70.3 (SD = 4.7)

almost entirely white ( didn’t mention %)

48.2% females, 51.8% male

1.6% full vaccinated ,97.1% received at least one dose

longitudinal study

colombia ,El Salvador and spain

August to december 2021

18–25year>> (40.2%),26–35year >> (17.8%),36–50year>> (25.8%),51–64year>> (12.4%),>65year >>> (3.9%)

66.7% females, 33.3% male

Low 703 (23.2%),Medium 782 (25.8%),High 1541 (50.9%)

Students/Unemployed/Retired. 1042 (no % given)
Administrative staff (0.7%)
Auxiliary or technician (4.6%)
Commercial (1.1%)
Nurse (8.7%)
Medical Doctor (MD) (7.3%)
Other health professionals different from MDs or nurses (4.0%)
Non-sanitary (39.2%)

Kim Mannemar Sønderskov

30 August to 15 September 2021

female= 768(49.4%)/ male=78887(50.6%)

Pfizer/BioNTech, Moderna, johnson, astrazeneca & compination

vaccinated or planed =1482(95.3%)

longitudinal study

female= (62.2%)/ male=(37.8%)

Pfizer/BioNTech&
BNT162b2 or the AstraZeneca ChAdOx1nCoV-19 vaccines

the majority (69.2%) had received their second dose

Clinical Role
Consultant 316 (24.7%)
Assistant consultant/fellow 93(7.3%)
Resident/registrar/physician in training 244 (19.1%)
Nurse 533 (41.7%)
Others: pharmacist, lab technician (radiology and anesthesia) 92( 7.2%)

28 January and 5 March 2022

Age Group
18–30 years old 212 (26.9%)
31–40 years old 246 (31.3%)
41–50 years old 192 (24.4%)
51–60 years old 98 (12.5%)
>60 years old 39 (5%)

females=485 (61.6%), males=302 (38.4%)

Vaccine Type
Sinovac 520 (66.1%)
Sinopharm 42 (5.3%)
AstraZeneca-Oxford 99 (12.6%)
Janssen 24 (3%)
Sputnik V 80 (10.2%)
Pfizer-BioNTech 4 (0.5%)
I do not know 18 (2.3%)

Non-Healthcare Professionals (n = 482)

Healthcare Professionals (n = 305)

HCW = 305 (38.8%) NON HCW=482(61.2%)

3 and 11 November 2021

46.97 +11.78 (IQR: 39–55) years old

Gender
Female † 2796 (80.9%)
Male 643 (18.6%)
LGBTQ+ 15( 0.4%)

BTN162b2 (90.7%), followed by mRNA-1273 (5.3%), AZD1222 (2.7%), and
Ad26.COV2.S (1.3%).

Less than half of the sample received a third dose by the time of responding to this survey (48.5%), and the rest received either two doses (49.7%) or one dose (1.8%).

Medical Professionals (MP) 1047 (30.3%)
Allied Health Professionals (AHP) 2407( 69.7%)

San Mateo, CA, USA

18 October 2021 and 29 November 2021

18–29 years old 883 (51)
30–39 years old 250 (14)
40–49 years old 196 (11)
50–59 years old 223 (13)
60–69 years old 129 (7)
70+ years old 65 (4)

Half were immigrants (n = 871, 50%) and 43% (n = 753) were born and raised in the US/ Arabian Peninsula 64 (4%)
Fertile Crescent 1667 (95%)
Greater Maghreb 15 (1%)

Nearly all (95%) either already received or planned on receiving their second dose

Less than a high school degree 12 (1%)
High school degree or GED 144 (8%)
College 295 (17%)
Associate’s degree 78 (4%)
Bachelor’s degree 505 (29%)
Master’s degree 270 (15)
Doctorate 442 (25)

Zhongmou County, Henan Province,China

August 6, 2021 and August 9

Age (years) mean 30.99
18–29 13,312(44.48%)
30–39 11,911(39.80%)
40–49 3,269(10.92%)
50–59 1,149(3.84%)
60– 284 (0.95%)

Ethnic groups
Han 28,579(95.50%)

Minority 1,346 (4.50%)

Sex
Men 14,556(48.64%)
Women 15,369(51.36%)

a face-to face interview with participants from a representative village/ THEN A subsequent national cross-sectional online

Chronic condition
0 no chronic diseases 24,960 (84.95%)
1chronic disease 3,245(11.04%)
2 chronic diseases 891 (3.03%)
≥3chronic diseases 287 (0.98%)

Educational status
Below high school 3,839(12.83%)
High school graduate 7,893 (26.38%)
University graduate 18,193 (60.80%)

1 February 2021 and 31 March 2021

Age *
18–30 170(12.5%)
31–40 384(28.3%)
41–50 292(21.5%)
51–60 294(21.6%)
>60 208(15.3%)

Racial identity *
Asian 91 (6.7%)
Black 43 (3.2%)
White 1132 (83.4%)
Other 81 (6.0%)

Gender *
Female 1076 (79.2%)
Male 273 (20.1%)

1251received both doses or were planning to receive both doses of the vaccine/107 not vacinated hesitant to receive either the first or second dose

Education
GED or less 168 (12.4%)
Vocational 399 (29.4%)
Bachelors 250 (18.4%)
Masters 158 (11.6%)
Professional 383 (28.2%)

Occupation
DMP 542 (39.9%)
DPCP 514 (37.8%)
No direct contact 168 (12.4%)
Administration 134( 9.9%)

USA (Alaskan communities)

Data were collected via three survey waves. Wave 1: November 9 through 15 December 2020; Wave 2: March 9 to 25 March 2021; Wave 3: September 2–27)

African American: 1.7, Alaska Native: 59.8, Asian: 1.5, White: 29.4, Latino: 0.3, More than one: 7.4

Males: 30.1, Females: 69.9

longitudinal study

Males: 41.7 Females: 58.3

mRNA-1273, BNT162b2

retrospective cohort study

18-29: 206 (27.7), 30-59: 503 (67.6), > 59: 35 (4.7)

Males: 35, Females:65

Most of the respondents (93.4% n = 695) had received at least one dose of a SARS-CoV-2 vaccine at the time of the survey (mainly CoronaVac and Pfizer)

Middle School: 5 (0.7), High School: 273 (36.7), Undergraduate: 311 (41.8), Postgraduate: 155 (20.8)

16 November and 6 December 2021

Males: (42.6), Females: (57.4)

of total respondents 73(11.9%) have at least one chronic condition

High school degree or
less (69.3%), Baccalaureate/Graduate
degree (30.7%)

Student (71.1%), Other (28.9%)

Gede Benny SetiaWirawan

during 6th to 16th February

Age (years), median (IQR): 29 (24–35)

Male: (42), Females: (58)

Not completed high school: (8.3%), Completed high school: (52.8), Completed college: (38.9)

Unemployed: (12.7), Stay-at-home wife: (24.6), Student: (11.9), Part-time employment: (18.3), Full-time employment: (32.5)

Dec., 2021 & Jan., 2022

25–34: 19.9%, 35–44: 46.9%, 45–54: 23%, 55–64 or older: 10.2%

Saudi: 79.6, Non-Saudi: 20.4

Female/mother: 65.3, Male/father: 34.7

Yes: the primary two doses: 61.3%, Yes: with the third booster dose: 35%, No: due to a medical exception: 0.5%, No: I do not believe in the COVID-19 vaccine: 2.6%, Not received due to other causes: 0.6%

High school or less: 12.3%, University Degree: 76.4, Higher studies (Master’s or PhD): 11.3

Unemployed/Retired: 21.8%, Freelance: 8.2%, Healthcare worker: 23%, Employee: 47%

November 2021, February 2022

(mean = 32.1, SD ±11.3)

Malay: 44%, Chinese: 22.1%, Indian: 25.7%, Bumiputera Sabah/Sarawak: 2.1%, Others: 6.1%

Males (36.3), Female (63.7%)

93(9.2) had been diagnosed with chronic condition

Professional and managerial: 37.9%, General worker: 13.7%, Self-employed: 5.9%, Student: 31.2%, Housewife/Retired/Unemployed:11.3%

18-29: 40.4%, 30-39: 34.2%, 40-49: 12.8%, 50-59: 8.4%, ≥60: 4.2%

Male: 24, Female: 76

Primary/secondary: 6.7%, Bachelor: 51.4%, Diploma: 8.0%, Graduate studies: 33.9%,

Employed: 57.5%, Unemployed: 37.5%, Retired: 5%

18–19(0.3%), 20–29(78.8%), 30–39(10.4%), 40–49(5.7%), Prefer not to answer(0.3%)

White(57.6%), Black or African American(3.8%), American Indian or Alaskan Native(0.3%), Asian(25.9%), Native Hawaiian or other Pacific islander(0%), From multiple races(5.4%), Other(3.2%), Prefer not to answer(3.8%)

Female(47.2%), Male(50.0%), Other(0.6%), Prefer not to answer(1.6%)

Pfizer-BioNTech(60.5%), Moderna(34.2%), J&J/Janssen(5.3%)

Medical students enrolled at two different cam-puses (Jonesboro, AR and Old Westbury, NY, USA)

Sociodemographic characterstics ; Age, gender, Marital status, Race/Ethnicity, Household income, campus location, Vaccine type

21 March 2020 to 6 December 2021

Age
60+ mean 0-43. SD 0-50
45-59 mean 0-34 SD 0-47
30-44. mean 0-19 SD 0-39
18-29 mean 0-04. SD 0-19

males and females

Undergraduate degree or higher mean 0-71 SD 0-46
A-levels or vocational mean 0-16 SD 0-37
Up to GCSE mean 0-13 SD 0-34

Not employed mean 0-42 SD 0-49
Employed mean 0-58. SD 0-49

individuals who
had (i) data on intent to receive a COVID-19 booster vac-
cine (collected 22 November to 6 December 2021, here-
after ‘follow-up’), (ii) data on initial intent to receive a
first COVID-19 vaccine (collected 2 December 2020 to
31 March 2021), (iii) received at least two doses of a
COVID-19 vaccine at follow-up, and (iv) complete data
on other study variables.

individuals were excluded due to miss-
ing data on other study variables, for example those
who had selected “other/prefer not to say” in response
to gender or “prefer not to say” on ethnicity or income,
due to insufficient statistical power and an inability to
create statistical weights for these individuals,

between 2 December and 8 December 2021 (7 days).

74.2 % female, 25.8% male

Medical doctor 48 13.2% Nurse 220 50.9 % Other medical staffs 51 12.4%Administrative staffs 94 23.5%

medical staff at Sakaide City Hospital, Sakaide

682 (73.3%) were females, 232 (24.9%) were males

the most commonly administered vaccine was BNT162b2

Over 95% of the participants had received at least one vaccine dose

322 were employees and 608 were students

(a) students who were enrolled in degree programs, and (b) academic and non-academic employees of German universities.

50.31% were female

s Chinese adults living in the mainland of China, aged 18–59 years old

18–24 8.5% 10.8%
25–44 30.7% 31.2%
45–64 34.2% 32.4%
65+ 26.7% 25.6%

51.8% were female

69.8% received at least one dose

1 January 2021 to 10 December 2021

Study was extended to all aged ≤ 59

85.1 % were female

Pfizer-BioNTech/Comirnaty vaccine

high school/technical school College/associate/bachelor’s degree or above (100%)

54% were female ((46 %) were males

a retrospective observational study

Between 6 August 2021 and 9 August 2021

chinese(HAN25,741 (96.2)-MINORITY1014 (3.8))

12,685 (47.4)M-14,070 (52.6) F

Chronic condition(Yes 3251 (12.2)-No 23,504 (87.8))

Below high school2948 (11.0)-High school graduate7032 (26.3)-University graduate16,775 (62.7)

resident on chinese main land -above 18 -vaccinated or have been vaccinated

less than 18-not resident on chinese mainland-incomplete information on age- notvaccinated

Urban Bangkok, Thailand

September to December 2021

over18(42 ± 17.73.)

188 (24.1)M- 592 (75.9)F

noline survay -snowballsampling

Inactivated vaccine21 (2.7)    Viral vaccine120 (15.4)    mRNA vaccine225 (28.8)

aged 18 years and older living in Bangkok-took the first dose

less than 18 _ not live in bankok -did not take first dose

over two weeks starting 11 January 2022,

White 196 (61.4%)-Black or African American9 (2.8%)-American Indian or Alaskan Native 2 (0.6%)-Asian 73 (22.8%)-Native Hawaiian or other Pacific Islander 0 (0%)-From multiple races 14 (4.4%)-others 8 (2.5%)--prefer not to answer 17 (5.3%).

164 (51.4%)f-140 (43.8%)m-5 (1.6%)other -6 (1.9%)Prefer not to answer

 student or preclinical at New York Institute of Technology College of Osteopathic Medicine (NYITCOM)

African Americans (n = 2,281),-Latino/a (n = 2,944)-Asian Americans and Pacific Islanders (n = 2,281)-American Indians/Native Americans (n = 1,921).

51.1%f - 48.9%m

mixed-mode (telephone and online) poll 

High school or less40.0%-Some college, not graduate30.2%-College graduate/ post graduate degree30.0%

mean age, 69.19 years (SD = 6.1);>or =60

53%academic education.

adults (35-40 years old)

males and females

Junior high school and
below 105 (6.4) 135 (33.5)
Senior high school 78 (4.7) 216 (53.6)
Associate or bachelor Master and above

vaccinated  Chinese  adults

 Incomplete  questionnaires
were  excluded

adults 45,9% ((18-29 years old))

males and females

Pfizer, AstraZeneca , Sinopharm.

High school
Diploma
University student 168
Bachelor
Postgraduate

Age 0.052 0.097 0.178
≥40 years 827 (52.5)
<40 years 749 (47.5)

Male 363 (23.0)
Female 1213 (77.0)

Education level
Senior Secondary
and below
778 (49.4)
University and above 798 (50.6)

all parents who received the invitation letter and volun-
teered to complete the questionnaire.

excluding those
who were under the age of 18 or over the age of 70, excluding
those who answered within 120 seconds

above 18 years old

males and females

unfull vaccinated (n =69) 6.8% and fully vaccinated (n=326) 32,5%

High school 253
Bachelor degree 228
Master degree 385
Postgraduate degree 51
PhD 86

The only criterion for participation
in the investigation was that the respondents were over 18 years old.

Aged <50, % (n) 62.3 (1513)
Aged ≥50, % (n) 37.7 (914)

Female, % (n) 50.7 (1231)
Male, % (n) 49.3 (1196)

BNT162b2, mRNA-1273 , AZD1222, Ad26.COV2.

Primary, % (n) 1.5 (37)
Secondary, % (n) 3.5 (85)
Vocational, % (n) 24.4 (591)
Tertiary, % (n) 70.6 (1714)

age ≥ 18 years old, Polish nationality, and status of the fully vaccinated individual

Frederik Juhl Jørgensen

from 15 December 2021 to 13 February 2022

they do not specify the specific vaccine, but the available vaccines in the Danish vaccination program are the vaccines developed by Pfizer/BioNTech and Moderna

full sample (all participants) / primary vaccination sample (either are (1) fully vaccinated (received two doses), (2) partially vaccinated (received one dose), or (3) wish to be vaccinated but had previously refused an invitation)

Danish citizens aged 18 or older

from 15 September to 8 October 2021

guardians of children aged <6 years in China

294 males (59.27%), 202 females (40.73%)

All participants 90.7% (450/496)
Completed second dose vaccine 84.5% (419/496)

medical students at Dokkyo Medical University

medical students at Dokkyo Medical University

from 1 October 2021 to 30 November 2021

1023 males (49.7%), 1036 females (50.3%)

39.8% (819/2059) definitely yes
31.3% (645/2059) probably yes
71.1% (1464/2059) intention for the COVID-19 booster dose uptake

healthcare workers working in Saudi Arabia who were above 18 years of age

23 May to 30 May 2022

195 Male (23.9%)
620 Female (76.1%)

aged 18 years or above, had to understand the Greek language, and have completed a COVID-19 vaccine course (i.e., first COVID-19 doses and a booster dose)